Clinical Trial Update: A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma. [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update reports on the evaluation of GW685698X given once daily (100 mcg in the morning or evening) and 250 mcg once daily in the eve…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• GW685698X

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 2 | Status: COMPLETED